NRXS · NeurAxis, Inc.

This 8-K updates investors on the status and expansion of NeurAxis’s at-the-market (ATM) equity offering program initiated in August 2025. The disclosure confirms that over 1.12 million shares have already been sold — representing meaningful execution against the original $6.27 million cap — and that the company has now doubled its available capacity to $11.5 million. While no specific use-of-proceeds breakdown beyond 'general corporate purposes' is provided, the timing and scale suggest continued funding needs likely tied to clinical development, regulatory activities, or working capital. The reliance on an existing effective shelf registration (S-3) streamlines execution and avoids delays associated with new filings. The inclusion of a legal opinion (Exhibit 5.1) reinforces the enforceability and validity of the issuance mechanics, reducing counterparty and settlement risk for investors. Though not a new financing event per se, the update signals sustained reliance on equity capital and may foreshadow further sales, warranting monitoring of share count and cash balance trends in upcoming quarterly reports.